HALO · Halozyme Therapeutics, Inc.
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-05-11 | $1,000,000,000 | $824,900,000 | 2026-06-30 | 2028-12-31 | 10-Q , filed 2026-08-06 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-06-30 YTD | $332,729,000 | 10-Q, filed 2026-08-06 | ||
| 2025-12-31 | $342,372,000 | 10-K, filed 2026-02-17 | ||
| 2024-12-31 | $250,000,000 | 10-K, filed 2026-02-17 | ||
| 2023-12-31 | $402,383,000 | 10-K, filed 2026-02-17 | ||
| 2022-12-31 | $200,002,000 | 10-K, filed 2025-02-18 | ||
| 2021-12-31 | $350,058,000 | 10-K, filed 2024-02-20 | ||
| 2020-12-31 | $150,117,000 | 10-K, filed 2023-02-21 | ||
| 2019-12-31 | $199,998,000 | 10-K, filed 2022-02-22 | ||